Delivery Order SPE2DB24D2010-SPE2DB25FAAYB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price delivery order carries a ceiling value of $7,030.77 and is scheduled for completion by September 12, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within...
- The Defense Logistics Agency awarded a delivery order valued at $9,374.36 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors, with an ultimate completion date of August 22, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order for pharmaceutical products to support federal medical supply needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a $2,343.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen auto-injectors on August 11, 2025, with completion targeted for September 2, 2025. This is a non-set-aside, competitively awarded contract under which AmerisourceBergen will deliver the specified pharmaceutical product to support federal medical supply needs. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors, valued at $2,343.59, with a completion date of August 26, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply requirements. The work will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $4,687.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitively awarded, firm fixed-price contract with an ultimate completion date of September 3, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $9,374.36 on August 18, 2025, with completion scheduled for September 9, 2025. The contract covers the supply of Tezspire 210 mg/1.91 mL pen auto-injectors and was funded through the Defense Logistics Agency's Medical Supply Chain division. This firm fixed-price delivery order represents a non-set-aside award, indicating open...
- The Defense Logistics Agency awarded a delivery order valued at $7,030.77 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. The contract is non-competitive, firm fixed price delivery order with an ultimate completion date of September 8, 2025. Performance will occur at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under a larger Indefinite Delivery Contract vehicle with the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,343.59 firm fixed price delivery order on August 25, 2025, for Tezspire 210 mg/1.91 mL pen medication with a completion date of September 16, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger federal contract portfolio with DLA. The delivery order is to be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 ml pen auto-injectors on July 31, 2025. This firm fixed-price, non-set-aside contract is scheduled for completion by August 21, 2025, with performance taking place at the vendor's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order valued at $2,343.59 to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 22, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Tezspire is a specialty pharmaceutical treatment used in respiratory and immunological applications, reflecting the...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FAAYBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Tezspire 210 mg/1.91 mL pen auto-injectors, valued at $2,343.59 with a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of September 16, 2025. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a standard pharmaceutical procurement transaction within the Defense Logistics Agency's medical supply chain operations. This delivery order is issued under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. As a major pharmaceutical distributor headquartered in Pennsylvania, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical devices across multiple therapeutic areas. The company's consistent success in competitive federal procurements demonstrates its capability to meet demanding federal medical supply requirements and support healthcare delivery for the Defense Health Agency and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/25/25 |